Archivierte Dokumente
- Abemaciclib (Verzenios®)
- Abirateronacetat (Zytiga®)
- Abirateronacetat (Zytiga®) nach Docetaxel
- Afatinib (Giotrif®)
- Aflibercept (Zaltrap®)
- Albutrepenonacog alfa (Idelvion®)
- Alectinib (Alecensa®)
- Apixaban (Eliquis®)
- Atezolizumab (Tecentriq®)
- Axitinib (Inlyta®)
- Binimetinib (Mektovi®)
- Blinatumomab (Blincyto®)
- Bosutinib (Bosulif®)
- Brentuximab Vedotin (Adcetris®)
- Brigatinib (Alunbrig®)
- Cabazitaxel (Jevtana®)
- Cabozantinib (Cabometyx®)
- Cabozantinib (Cometriq®)
- Carfilzomib (Kyprolis®)
- Carfilzomib (Kyprolis®) (Stand Oktober 2021)
- Carfilzomib (Kyprolis®) (Stand Februar 2018)
- Carfilzomib (Kyprolis®) (Stand Februar 2018)
- Carfilzomib (Kyprolis®) (Stand September 2017)
- Carfilzomib (Kyprolis®) (Stand September 2017)
- Carfilzomib (Kyprolis®) (Stand April 2017)
- Carfilzomib (Kyprolis®) (Stand Oktober 2016)
- Carfilzomib (Kyprolis®) (Stand Juni 2016)
- Carfilzomib (Kyprolis®), Dexamethason
- Ceritinib (Zykadia®)
- Cladribine
- Cobimetinib (Cotellic®)
- Crizotinib (Xalkori®)
- Crizotinib (Xalkori®) Zweitlinientherapie
- Dabrafenib (Tafinlar®)
- Daratumumab (Darzalex®)
- Decitabin (Dacogen®)
- Edoxaban (Lixiana®)
- Efmoroctocog alfa (Elocta®)
- Eftrenonacog alfa (Alprolix®)
- Elotuzumab (Empliciti®)
- Encorafenib (Braftovi®)
- Enzalutamid (Xtandi®)
- Eribulin (Halaven®)
- Fidaxomicin (Dificlir®)
- Ibrutinib (Imbruvica®)
- Ibrutinib (Imbruvica®) bei CLL
- Ibrutinib (Imbruvica®) bei Mantelzell-Lymphom
- Idelalisib (Zydelig®)
- Idelalisib (Zydelig®) bei CLL
- Idelalisib (Zydelig®) bei Follikulärem Lymphom
- Inotuzumab Ozogamicin (Besponsa®)
- Ipilimumab (Yervoy®)
- Isavuconazol (Cresemba®)
- Ixazomib (Ninlaro®)
- Lenvatinib (Kisplyx®)
- Lenvatinib (Lenvima®)
- Lonoctocog alfa (Afstyla®)
- Midostaurin (Rydapt®)
- Necitumumab (Portrazza®)
- Netupitant / Palonosetron (Akynzeo®)
- Nintedanib (Vargatef®)
- Nivolumab (Opdivo®)
- Nivolumab (Opdivo®) (Stand Mai 2018)
- Nivolumab (Opdivo®) (Stand Februar 2018)
- Nivolumab (Opdivo®) (Stand Februar 2018)
- Nivolumab (Opdivo®) (Stand Februar 2018)
- Nivolumab (Opdivo®) (Stand September 2017)
- Nivolumab (Opdivo®) (Stand September 2017)
- Nivolumab (Opdivo®) (Stand September 2017)
- Nivolumab (Opdivo®) (Stand September 2017)
- Nivolumab (Opdivo®) (Stand September 2017)
- Nivolumab (Opdivo®) (Stand August 2017)
- Nivolumab (Opdivo®) (Stand April 2017)
- Nivolumab (Opdivo®) (Stand Januar 2017)
- Nivolumab (Opdivo®) (Stand Januar 2017)
- Nivolumab (Opdivo®) (Stand Oktober 2016)
- Nivolumab (Opdivo®) bei Lungenkarzinom, nicht-kleinzellig (NSCLC), Plattenepithelkarzinom
- Obinutuzumab (Gazyvaro™)
- Obinutuzumab (Gazyvaro™) bei Follikulärem Lymphom
- Olaparib (Lynparza™)
- Olaratumab (Lartruvo™)
- Osimertinib (Tagrisso®)
- Palbociclib (Ibrance®)
- Panobinostat (Farydak®)
- Pembrolizumab (Keytruda®)
- Pembrolizumab (Keytruda®) bei Melanom
- Pentostatin (Nipent®)
- Pertuzumab (Perjeta®)
- Pixantron (Pixuvri®)
- Pomalidomid (Imnovid®)
- Ponatinib (Iclusig®)
- Radium-223 (Xofigo®)
- Ramucirumab (Cyramza®)
- Regorafenib (Stivarga®)
- Regorafenib (Stivarga®) bei kolorektalem Karzinom
- Ribociclib (Kisqali®)
- Rolapitant (Varuby®)
- Ruxolitinib (Jakavi®)
- Siltuximab (Sylvant®)
- Simoctocog alfa (Nuwiq®)
- Sonidegib (Odomzo®)
- Tivozanib (Fotivda®)
- Trametinib (Mekinist®)
- Trastuzumab Emtansin (Kadcyla®)
- Trifluridin / Tipiracil (Lonsurf®)
- Trifluridin Tipiracil (Lonsurf®)
- Turoctocog alfa (NovoEight®)
- Vandetanib (Caprelsa®)
- Vemurafenib (Zelboraf®)
- Venetoclax (Venclyxto®)
